Nivolumab Injectable Product Clinical Trials

3 actively recruiting trials across 3 locations

No change since May 2026

Also known as: OPDIVO, immune checkpoint inhibitor

Pipeline

Phase 1: 2Phase 2: 1

Top Sponsors

University of Rochester1
Teclison Ltd.1
Baylor College of Medicine1

Indications

Cancer3
Liver Disease1
Undifferentiated Sarcoma1
Synovial Sarcoma1
HER-2 Protein Overexpression1

Orange, California1 trial

Combination of TATE and PD-1 Inhibitor in Liver Cancer

University of California, Irvine

Phase 2

Rochester, New York1 trial

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

University of Rochester

Phase 1

Houston, Texas1 trial

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Texas Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.